血液・腫瘍内科学/内科学教室(血液・腫瘍内科学部門)

血液・腫瘍内科学 http://www.f.kpu-m.ac.jp/k/hematol/

大学院科目名 血液・腫瘍内科学部門
教室名 内科学教室(血液・腫瘍内科学部門)
スタッフ
准教授(兼)  堀池 重夫
講師      黒田 純也
講師(学内)  古林 勉
助教      志村 勇司 
研究内容
当教室では「臨床に役立つ血液・腫瘍学研究」をモットーに、
1.腫瘍発生に関連する染色体、遺伝子異常の同定と解析、臨床病態との関連性
    に関する研究

2.  新規分子標的治療の開発を目指した探索的基礎研究

3.  造血細胞移植を用いた造血器疾患の治療法開発

4.  造血器腫瘍の治療戦略確立に関わる臨床研究

5.  希有疾患や特殊治療の経験に関する症例報告

などを、スタッフが中心となって幅広く展開しています。
大学院生、専攻医はそれぞれが基礎研究、臨床研究の課題を担当し、臨床医、研究者としての思考プロセスと実践力の養成を目指しています。いずれの研究もスタッフの日常的な指導と同時に、教室の研究カンファレンスで進捗を確認し、方向性を議論しながら推進します。
研究成果は積極的に学会、論文等での発表を行い、血液内科学の発展への貢献を目指します。また、新しい研究を希望する人には国内外留学を積極的に推奨しています。
研究業績
Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, Isa R, Yamaguchi J, Kawata E, Akaogi T, Uchiyama H, Kaneko H, Uoshima N, Kobayashi Y, Teramukai S, Taniwaki M. The Kyoto Prognostic Index for patients with Diffuse Large B-cell Lymphoma in the Rituximab era. Blood Cancer J, 6: e383, 2016.
 
Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M, Okuda T. 
Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis.  Br J Haematol. 2015;170:859-73.
 
 Nagoshi H, Taki T, Chinen Y, Tatekawa S, Tsukamoto T, Maegawa S, Yamamoto-Sugitani M, Tsutsumi Y, Kobayashi T, Matsumoto Y, Horiike S, Okuno Y, Fujiwara S, Hata H, Kuroda J, Taniwaki M. Transcriptional Deregulation of the Deleted in Colorectal Carcinoma Gene in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. Gene Chromosome Canc,54:788-795, 2015.
 
Chinen Y, Kuroda J, Shimura Y, Nagoshi H, Kiyota M, Yamamoto-Sugitani M, Mizutani S, Sakamoto N, Ri M, Kawata E, Kobayashi T, Matsumoto Y, Horiike S, Iida S, Taniwaki M. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res, 74;7418-7429, 2014.
 
Chinen Y, Sakamoto N, Nagoshi H, Taki T, Maegawa S, Tatekawa S, Tsukamoto T, Mizutani S, Shimura Y, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S,  Kuroda J, Taniwaki M.8q24 amplified segments involve novel fusion genes between NSMCE2and long noncoding RNAs in acute myelogenous leukemias. J Hematol Oncol, 23; 68-72, 2014.

Chinen Y, Taki T, Tsutsumi Y, Kobayashi S, Matsumoto Y, Sakamoto N, Kuroda J, Horiike S, Nishida K, Ohno H, Uike N, Masafumi Taniwaki. The Leucine Twenty Homeobox (LEUTX) Gene, Which Lacks a Histone Acetyltransferase Domain, is Fused to KAT6Ain Therapy-Related Acute Myeloid Leukemia with t(8;19)(p11;q13).Gene Chromosome Canc53:299-308, 2014.

 Chinen Y, Taki T, Tsutsumi Y, Kobayashi S, Matsumoto Y, Sakamoto N, Kuroda J, Horiike S, Nishida K, Ohno H, Uike N, Masafumi Taniwaki. The Leucine Twenty Homeobox (LEUTX) Gene, Which Lacks a Histone Acetyltransferase Domain, is Fused to KAT6A in Therapy-Related Acute Myeloid Leukemia with t(8;19)(p11;q13). Gene Chromosome Canc 53:299-308, 2014.
 
Kiyota M, Kuroda J, Yamamoto-Sugitani M, Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N, Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis, 18:1437-46, 2013

Kuroda J, Nagoshi H, Shimura Y, Taniwaki M. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther. 13:1081-1088, 2013.
 
Tsutsumi Y, Chinen Y, Sakamoto N, Nagoshi H, Nishida K, Kobayashi S, Yokokawa Y, Taki T, Sasaki N, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M. Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality. Leuk Lymphoma. 54:2760-2764, 2013.
 
Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K, Okuda K, Sakamoto N, Kobayashi S, Yamamoto-Sugitani M, Tsutsumi Y, Kobayashi T, Matsumoto Y, Horiike S, Kuroda J, Taniwaki M. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res. 72:4954-4962, 2012.
 
Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther. 11:2600-2609, 2012.
 
Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Shimura Y, Kiyota M, Nakayama R, Akaji K, Taki T, Uoshima N, Kobayashi Y, Horiike S, Maekawa T, Taniwaki M. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA. 108:17468-17473, 2011.
 
Kobayashi S, Taki T, Chinen Y, Tsutsumi Y, Ohshiro M, Kobayashi T, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Identification of IGHCδ-BACH2 fusion transcripts resulting from cryptic chromosomal rearrangements of 14q32 with 6q15 in aggressive B-cell lymphoma/leukemia.Genes Chromosomes Cancer 50:207-216, 2011.
 
Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S, Hatake K, Yamauchi A, Hirashima M, Taniwaki M. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 24:843-850, 2010.

 

問い合わせ先
TEL:075-251-5740
FAX:075-251-5743
e-mail:taniwaki@koto.kpu-m.ac.jp
教室独自のHP http://www.f.kpu-m.ac.jp/k/hematol/
COPYRIGHT (C) 2012 KYOTO PREFECTURAL UNIVERSITY OF MEDICINE ALL RIGHTS RESERVED.